Sort by
Refine Your Search
-
globally, causing substantial disability and healthcare burden. Anti-CGRP monoclonal antibodies (mABs) have transformed migraine prevention, but questions remain about optimal treatment duration and outcomes
Enter an email to receive alerts for optimization-"UCL" positions